

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 3/9/1985
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Blood Culture, AFB and Fungal

ARUP test code 0060024

Collected: 00/00/0000 00:00 MT
Started: 00/00/0000 00:00 MT

Source: **Blood**

Body Site:

Free Text Sources: **Blood Blood**

Final Report

Culture **POSITIVE** for
Mycobacterium avium-intracellulare complex
Identification by MALDI-TOF
This test was developed and its performance characteristics
determined by ARUP Laboratories. It has not been cleared or
approved by the U.S. Food and Drug Administration.
This test was performed in a CLIA-certified laboratory and
is intended for clinical purposes.

Susceptibility Results

Organism: Mycobacterium avium-intracellulare complex

| | |
|-----------------------|--|
| Amikacin | Interpretation: SUSCEPTIBLE MIC (ug/mL): 16 |
| Clarithromycin | Interpretation: SUSCEPTIBLE MIC (ug/mL): 1 |
| Linezolid | Interpretation: SUSCEPTIBLE MIC (ug/mL): 8 |
| Moxifloxacin | Interpretation: SUSCEPTIBLE MIC (ug/mL): 1 |

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate,
SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

Interpretive Information Interpretation: **SEE NOTE**

For Mycobacterium avium-intracellulare complex, CLSI recommends testing and reporting clarithromycin, moxifloxacin, amikacin and linezolid. The reported amikacin interpretation is for IV; if using amikacin (liposomal, inhaled), the MIC interpretive breakpoints are <=64 ug/mL Susceptible, >=128 ug/mL Resistant. The in vivo effectiveness of Moxifloxacin and Linezolid for MAC disease is unproven. Ethambutol, rifampin and rifabutin MIC results are not reported because MIC values are not predictive of clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology. Interpret results in conjunction with clinical presentation. Test developed and characteristics determined by ARUP Laboratories. See compliance Statement B: aruplab.com/CS.

| VERIFIED/REPORTED DATES | | | | |
|-------------------------------|---------------|------------------|------------------|-------------------|
| Procedure | Accession | Collected | Received | Verified/Reported |
| Blood Culture, AFB and Fungal | 23-090-135128 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |

END OF CHART

S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: